AstraZeneca to buy Fusion Pharma for $2 billion in cash

Fusion Pharmaceuticals

19/03/2024 07:07

March 19 (Reuters) - AstraZeneca  AZN.L  said on Tuesday
it has agreed to buy clinical-stage biopharmaceutical company
Fusion Pharmaceuticals Inc  FUSN.O  for about $2 billion in
cash.
    The drugmaker will pay $21 per Fusion share plus a
non-transferable contingent value right of $3 per share.

 (Reporting by Yadarisa Shabong in Bengaluru; Editing by Savio
D'Souza)
 ((Yadarisa.Shabong@thomsonreuters.com; +91 9742735150;))